VR Adviser’s Relmada Therapeutics RLMD Stock Holding History

VR Adviser’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.7M	Buy	+4,843,380	New	+$22.9M	1.26%	21
2022 Q4	–	Sell	-1,518,056	Closed	-$56.2M	–	33
2022 Q3	$56.2M	Sell	1,518,056 -752,016	-33%	-$20.8M	8.67%	4
2022 Q2	$43.1M	Hold	2,270,072	–	–	8.49%	3
2022 Q1	$61.3M	Hold	2,270,072	–	–	9.93%	3
2021 Q4	$51.1M	Buy	2,270,072 +882,352	+64%	+$19.6M	6.99%	4
2021 Q3	$36.4M	Hold	1,387,720	–	–	4.67%	9
2021 Q2	$44.4M	Buy	1,387,720 +534,514	+63%	+$18.6M	5.39%	6
2021 Q1	$30M	Buy	853,206 +184,766	+28%	+$6.46M	3.26%	12
2020 Q4	$21.4M	Hold	668,440	–	–	3.15%	10
2020 Q3	$25.1M	Hold	668,440	–	–	4.92%	7
2020 Q2	$29.9M	Sell	668,440 -174,374	-21%	-$7.37M	7.16%	4
2020 Q1	$28.7M	Buy	+842,814	New	+$34M	7.79%	3

Other funds holding RLMD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

SSC

Spruce Street Capital New York $416M AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

VR Adviser's RLMD Position: Q1 2026 in Review

VR Adviser opened a new position in Relmada Therapeutics (RLMD) in Q1 2026: 4,843,380 shares worth $33.7M. The stake represents 1.26% of the portfolio and ranks #21 among its holdings. This is a return to the name: VR Adviser previously reported a position in RLMD as recently as Q3 2022.

VR Adviser first reported a position in RLMD in Q1 2020 and has held it in 12 quarters since. The position peaked at $61.3M in Q1 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

VR Adviser held 4,843,380 shares of Relmada Therapeutics worth $33.7M as of Q1 2026.
Relmada Therapeutics was a new VR Adviser position in Q1 2026.
Relmada Therapeutics made up 1.26% of VR Adviser's portfolio in Q1 2026, its #21 holding.
VR Adviser first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 12 quarters since.
VR Adviser's Relmada Therapeutics position peaked at $61.3M in Q1 2022.
103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.